Patents by Inventor Craig Pace

Craig Pace has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA REPLICON VACCINES AGAINST HBV
    Publication number: 20220016237
    Abstract: Nucleic acid molecules encoding hepatitis B virus (HBV) surface antigens, HBV core antigens, and HBV polymerase antigens, and related combinations, are described. Also described are vectors, such as DNA plasmids or viral vectors, and RNA replicons, expressing the HBV antigens, and pharmaceutical compositions containing the expression vectors. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the pharmaceutical compositions of the invention are also described.
    Type: Application
    Filed: July 8, 2021
    Publication date: January 20, 2022
    Inventors: Jason L. DEHART, Nathaniel Stephen WANG, Parinaz ALIAHMAD, Christian MAINE, Heather Lynn DAVIS, Craig PACE
  • Fusion antibodies for HIV therapy
    Patent number: 8637024
    Abstract: Disclosed herein are fusion antibodies created to provide both an antigen-binding site that targets the CD4 receptor and an antigen-binding site that targets the HIV envelope. The fusion antibodies disclosed herein provide improved potency and breadth against HIV as compared to monospecific antibodies, and additionally provide high barrier against viral resistance. Also disclosed are pharmaceutical formulations and therapeutic methods utilizing such fusion proteins.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: January 28, 2014
    Assignee: The Rockefeller University
    Inventors: David Ho, Yaoxing Huang, Craig Pace, Ruijiang Song, Qing Fang
  • FUSION PROTEINS FOR HIV THERAPY
    Publication number: 20120121597
    Abstract: Disclosed herein are fusion antibodies created to provide both an antigen-binding site that targets the CD4 receptor and an antigen-binding site that targets the HIV envelope. The fusion antibodies disclosed herein provide improved potency and breadth against HIV as compared to monospecific antibodies, and additionally provide high barrier against viral resistance. Also disclosed are pharmaceutical formulations and therapeutic methods utilizing such fusion proteins.
    Type: Application
    Filed: November 11, 2011
    Publication date: May 17, 2012
    Applicant: THE ROCKEFELLER UNIVERSITY
    Inventors: David Ho, Yaoxing Huang, Craig Pace, Ruijiang Song, Qing Fang